POINT Biopharma Global Inc.
POINT Biopharma Global Inc. (PNT) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · PNT · as of Jun 9, 2026
Activity summary
Buy transactions
8
P-Purchase only
Sell transactions
1
12 Months
Buy/Sell ratio
8.00
Buy/Sell (by trades)
Overall sentiment
POINT Biopharma Global Inc. insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
PNT insider buying and selling by quarter
PNT insider selling · PNT insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Recent insider transactions
PNT executive sell shares · PNT board member insider trading · PNT insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Dec 26, 2023 | GOODMAN JONATHAN R. Director | Other | 41,872 | $523K | Form 4 |
| Dec 22, 2023 | MCCANN JOE A. CEO · Director | Other | 3,494,153 | $43.68M⚡ | Form 4 |
| Dec 22, 2023 | FLESHNER NEIL E. Chief Medical Officer · Director | Other | 358 | $4K | Form 4 |
| Dec 26, 2023 | HOGUE GERALD L. Director | Other | 21,596 | $270K | Form 4 |
| Dec 26, 2023 | Malik Rajesh Director | Other | 3,700 | $46K | Form 4 |
| Dec 26, 2023 | Lubner David Charles Director | Other | 35,400 | $443K | Form 4 |
| Dec 27, 2023 | Lubner David Charles Director | Other | 3,600 | $45K | Form 4 |
| Dec 22, 2023 | SILBER ALLAN C Executive Chairman · Director | Other | 71,744 | $897K | Form 4 |
| Dec 27, 2023 | MARGOLIN YAEL Director | Other | 1,710 | $21K | Form 4 |
| Nov 6, 2023 | MCCANN JOE A. CEO · Director | Gift | 120,000 | — | Form 4 |
| Nov 3, 2023 | SILBER ALLAN C Executive Chairman · Director | Gift | 500,000 | — | Form 4 |
| Oct 31, 2023 | FLESHNER NEIL E. Chief Medical Officer · Director | Gift | 250,000 | — | Form 4 |
| Mar 21, 2023 | HOGUE GERALD L. Director | Option | 17,936 | $125K | Form 4 |
| Nov 29, 2022 | MCCANN JOE A. CEO | Purchase | 2,160 | $14K | Form 4 |
| Nov 23, 2022 | Lubner David Charles Director | Purchase | 3,600 | $25K | Form 4 |
| Nov 25, 2022 | HOGUE GERALD L. Director | Purchase | 3,660 | $25K | Form 4 |
| Nov 28, 2022 | Malik Rajesh Director | Purchase | 3,700 | $25K | Form 4 |
| Nov 21, 2022 | MARGOLIN YAEL Director | Purchase | 1,710 | $11K | Form 4 |
| Nov 18, 2022 | GOODMAN JONATHAN R. Director | Purchase | 6,000 | $38K | Form 4 |
| Nov 18, 2022 | SILBER ALLAN C Executive Chairman | Purchase | 22,397 | $146K | Form 4 |
| Nov 17, 2022 | SILBER ALLAN C Executive Chairman | Purchase | 27,603 | $166K | Form 4 |
| May 25, 2022 | FLESHNER NEIL E. Chief Medical Officer | Sale | 564,204 | $4.24M⚡ | Form 4 |
MCCANN JOE A.
CEO · Director
Date
Dec 22
Shares
3,494,153
Price
$12.50
Value
$43.68M ⚡
FLESHNER NEIL E.
Chief Medical Officer · Director
Date
Dec 22
Shares
358
Price
$12.50
Value
$4K
SILBER ALLAN C
Executive Chairman · Director
Date
Dec 22
Shares
71,744
Price
$12.50
Value
$897K
SILBER ALLAN C
Executive Chairman · Director
Date
Nov 3
Shares
500,000
Price
—
Value
—
FLESHNER NEIL E.
Chief Medical Officer · Director
Date
Oct 31
Shares
250,000
Price
—
Value
—
SILBER ALLAN C
Executive Chairman
Date
Nov 18
Shares
22,397
Price
$6.50
Value
$146K
SILBER ALLAN C
Executive Chairman
Date
Nov 17
Shares
27,603
Price
$6.00
Value
$166K
FLESHNER NEIL E.
Chief Medical Officer
Date
May 25
Shares
564,204
Price
$7.51
Value
$4.24M ⚡
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About PNT insider trading
PNT insider trades
POINT Biopharma Global Inc. (PNT) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including PNT. Over the past 12 months, 0 insiders have filed transactions with the SEC. PNT insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For POINT Biopharma Global Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
PNT insider trading · 5 questionsThe insiders of POINT Biopharma Global Inc. (PNT) include executives and directors such as PNT, among others. Over the past 12 months, 0 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026